Skip to the main content

Review article

MOLECULAR BASIS OF BREAST CANCER RELATED TO BRCA 1 AND BRCA2 GENES: CHARACTERISTICS AND TARGETING THERAPY

SONJA LEVANAT
Mirela LEVAČIĆ CVOK


Full text: croatian pdf 105 Kb

page 34-37

downloads: 3.012

cite


Abstract

Breast cancer is one of the most frequent tumors in women, and BRCA1 and BRCA2 genes play a major role in the hereditary susceptibility for this disease. Until the age of 70 women carrying a mutation in BRCA1 or BRCA2 gene have a 45–85% probability of developing breast cancer, and 11–62% probability of developing ovarian cancer. Mutation carrier’s tumors contain nonfunctional BRCA1 or BRCA2 genes, which in healthy cells are involved in DNA repair. These tumors show an increased sensitivity to DNA damaging chemical agents and to PARP (poly(adenosine diphosphate-ribose) polymerase1) inhibitors. New targeted therapies already in use are directed toward tumors of mutation carriers. Successful treatment is most likely to be achieved through cooperation of a pathologist, oncologist and a genetic laboratory performing BRCA genes mutation screening.

Keywords

Breast neoplasms – genetics, pathology, drug therapy; Genes, BRCA1; Genes, BRCA2; Mutation – genetics; Antineoplastic agents – pharmacology

Hrčak ID:

63558

URI

https://hrcak.srce.hr/63558

Publication date:

28.2.2010.

Article data in other languages: croatian

Visits: 4.755 *